10 July 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

27 August 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the AMR Action Fund

The COVID-19 pandemic has stressed how drug and vaccine development requires time and resources. Whilst we welcome the launch of…

28 August 2020 - BEAM Alliance

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

BEAM News
Member News
Events

Latest news of BEAM Alliance

28 August 2020 - BEAM Alliance

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

27 August 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the AMR Action Fund

The COVID-19 pandemic has stressed how drug and vaccine development requires time and resources. Whilst we welcome the launch of…

10 July 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

02 April 2020 - BEAM Alliance

Request for Proposals (RFP) for an Agreement for Performance of Work (APW) to develop an online e-learning course on antimicrobial stewardship

To support the Antimicrobial Stewardship and Awareness (ASA) Unit in the Global Coordination and Partnership on Antimicrobial Resistance (GCP) department…

03 December 2019 - BEAM Alliance

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

The aim of the IMI Antimicrobial Resistance (AMR) Accelerator is to progress the development of new medicines to treat or…

18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

page 1/4

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

14 October 2020 - Polyphor Ltd

Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program

We are encouraged by the progress we have made in implementing Polyphor’s renewed strategy to advance our pipeline in oncology…

13 October 2020 - Nabriva Therapeutics GmbH

Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for administration in humans discovered and developed by the Nabriva Therapeutics team.…

29 September 2020 - Aptorum Group Ltd

Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome

RPIDD is an innovative liquid biopsy-driven rapid pathogen molecular diagnostics technology with proprietary and patented technologies being developed to deplete…

21 September 2020 - Alaxia

Alaxia breaks new ground with lead compound ALX‑009 as virucidal agent

ALX-009 targets antibiotic-multi-resistant Gram negative bacteria (‘super bugs’) that are currently untreatable. It combines two endogenous substances: the hypothiocyanite ion…

10 September 2020 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

01 September 2020 - Aptorum Group Ltd

Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models

As part of Aptorum Group’s Acticule infectious disease platform, ALS-4 is a novel first-in-class small molecule developed in oral form…

page 1/22

Events

13 July 2020

Curious2020 – Future Insight Virtual Event

This event will feature three key global initiatives to support further advancement in science & technology, solving the challenges of…

09 July 2020

REVIVE Webinar: The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study

In this webinar, Anand Anandkumar and Kamini Walia will discuss: - Why is India one of the hotbeds of the…

09 July 2020

Webinar: Antimicrobial Resistance (AMR): Phenotypic vs. Target-Based Screening

The webinar intends to motivate a revision of the way we feed the research funnel with new ideas, new biology…

09 July 2020

Global Launch – Virtual Event from Berlin: NEW INITIATIVE TAKES ON THE ANTIBIOTIC INNOVATION CHALLENGE

The world is losing its most powerful tool in healthcare: antibiotics. We need to take action now. Organized by IFPMA,…

30 June 2020

REVIVE Webinar: Clinical development of antimicrobials – Phase 1 development challenges

Speaker: Markus Zeitlinger, Head of Department of Clinical Pharmacology, Medical University of Vienna (Austria)

25 June 2020

REVIVE Webinar: Putting children first in the fight against antibiotic resistance

Speakers: - Dr Christina Obiero, co-investigator for GARDP fosfomycin clinical trial in Kilifi, Kenya - Dr Manica Balasegaram, Executive Director,…

25 June 2020

JPIAMR webinar series on antibiotic use and the risk for increased antibiotic resistance in the COVID-19 pandemic

The burden of AMR is likely to increase due to the escalated use of antibiotics to treat bacterial co-infections in…

25 June 2020

tranScrip: COVID-19 Panel Discussion: Successful Medical Affairs in the “New Normal” after COVID-19

During this hour-long panel discussion, we will hear from those embracing virtual medical affairs in a world with COVID-19.

25 June 2020

tranScrip is delighted to announce that one of the trials they have been involved in running on COVID 19 has generated positive results

tranScrip is a specialist drug development and lifecycle management service provider based in the UK with small satellite offices in…

page 2/8